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According to the current clinical practice guidelines for chronic obstructive pulmonary disease (COPD), the addition
of inhaled corticosteroids (ICS) to long-acting β2 agonist therapy is recommended in patients with moderate-to-
severe disease and an increased risk of exacerbations. However, ICS are largely overprescribed in clinical practice,
and most patients are unlikely to benefit from long-term ICS therapy.
Evidence from recent randomized-controlled trials supports the hypothesis that ICS can be safely and effectively
discontinued in patients with stable COPD and in whom ICS therapy may not be indicated, without detrimental
effects on lung function, health status, or risk of exacerbations. This article summarizes the evidence supporting the
discontinuation of ICS therapy, and proposes an algorithm for the implementation of ICS withdrawal in patients
with COPD in clinical practice.
Given the increased risk of potentially serious adverse effects and complications with ICS therapy (including
pneumonia), the use of ICS should be limited to the minority of patients in whom the treatment effects outweigh
the risks.
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Chronic obstructive pulmonary disease (COPD) is as-
sociated with high morbidity and mortality worldwide,
[1] and continues to represent a significant public
health challenge. According to the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) rec-
ommendations, long-acting bronchodilators are the
mainstay of treatment in patients with COPD [2].
Similarly, all national guidelines for the management
of COPD in Europe recommend bronchodilators as
first-line therapy, regardless of clinical presentation or
phenotype [3].
Anti-inflammatory therapy with inhaled corticosteroids
(ICS) may be added to long-acting β2-agonists (LABAs) in* Correspondence: mmiravitlles@vhebron.net
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(http://creativecommons.org/publicdomain/zepatients with moderate-to-very severe COPD and exacer-
bations [2]. The ICS/LABA combination is more effective
than either of the individual drugs alone for improving
health status and lung function and reducing exacerba-
tions in these patients, [4–6] and may also be used in the
management of patients with asthma-COPD overlap
(ACO) [2, 7, 8]. However, regular ICS therapy is associated
with an increased risk of pneumonia, particularly in older
patients (aged ≥55 years) and those with severe disease, as
well an increased prevalence of oral candidiasis, skin
bruising and hoarse voice [2, 9, 10].
According to the GOLD strategy, patients with COPD
in group D (with a history of frequent exacerbations [≥2
in the past year], and a COPD Assessment Test [CAT]
score ≥ 10 or modified Medical Research Council score ≥
2) should receive first-line treatment with a LABA/long-
acting muscarinic antagonist (LAMA) combination [2].
ICS/LABA combination therapy may be considered as
first-line therapy in patients with suspected ACO or highle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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risk criteria, real-life data indicate that only a minority of
patients with COPD would be potential candidates for
ICS therapy [11, 12]. However, ICS prescribing rates (ei-
ther alone or as combination therapy) reportedly range
from 42% to 86%, regardless of COPD severity and
exacerbation risk [7, 13–18]. This high ICS usage signifi-
cantly increases the risk of serious pneumonia and other
respiratory infections [6, 19, 20].
In a 2015 Spanish consensus report, it was agreed that
ICS therapy should be added to long-acting bronchodila-
tors in patients with frequent exacerbations and in those
with ACO phenotype, but should not be added to LABA
therapy to improve lung function [21]. The expert panel
also agreed that ICS withdrawal in patients with stable
COPD was possible, although no consensus was reached
on how, when and in whom to discontinue ICS [21].
Algorithms for the withdrawal of ICS in patients
switched from GOLD D to C following the new GOLD
classification [22] and for the stepwise ICS withdrawal in
patients with COPD [23, 24] have previously been pro-
posed; however, complex treatment algorithms are often
difficult to adopt into clinical practice. To this end, sim-
plified treatment algorithms for COPD management
have been developed [25, 26].
As a follow-up to the previous Spanish consensus re-
port on ICS use in COPD, experts in COPD manage-
ment met with the aim of developing a simplified
strategy for ICS withdrawal in patients with COPD. This
article summarizes the evidence for the discontinuation
of ICS therapy and presents a potential algorithm for the
implementation of ICS withdrawal in clinical practice.
Effects of ICS therapy in patients with COPD
Anti-inflammatory effects
ICSs are very effective as anti-inflammatory therapy in pa-
tients with asthma. ICS therapy works by recruiting his-
tone deacetylase (HDAC) enzymes to inflammatory genes
that are being actively transcribed; this suppresses the ex-
pression of inflammatory proteins and results in decreased
airway inflammation [27]. Compared with asthma, ICS
therapy is less effective when used in the management of
COPD. The diminished anti-inflammatory effects of ICSs
in COPD may be caused by decreased HDAC expression
and enzyme activity, which has been observed in the al-
veolar macrophages of patients with COPD and is thought
to be mediated by oxidative stress [28, 29].
Although the anti-inflammatory effects of ICS therapy
are decreased in COPD compared with asthma, decreases
in airway inflammation with ICS have been reported in
patients with COPD. In a study of patients with moderate-
to-severe COPD, inhaled fluticasone/salmeterol for
13 weeks led to significant reductions in absolute biopsy
CD8+, CD4+, and CD45+ cell counts versus placebo, as wellas sputum differential neutrophil counts and sputum eosin-
ophils [30]. The Groningen Leiden Universities Corticoste-
roids in Obstructive Lung Disease (GLUCOLD)-1 study
has also shown significant reductions in sputum
neutrophils, macrophages, and lymphocyte counts with flu-
ticasone therapy over 30 months in patients with
moderate-to-severe COPD, while withdrawal of fluticasone
after 6 months led to increased bronchial CD3+, mast, and
plasma cell counts [31]. In a long-term observational
follow-up study (GLUCOLD-2), patients who discontinued
fluticasone after 30 months of treatment experienced an in-
crease in sputum inflammatory cells, as well as bronchial
T-lymphocytes and mast cells [32]. The GLUCOLD-2 study
also demonstrated a significant correlation between in-
creased sputum macrophage counts and an accelerated
rate of decline in lung function [32]. These studies
suggest that at least some patients with COPD, and
in particular those with significant airway inflamma-
tion, may benefit from ICS therapy. However, there is
also evidence that fluticasone may not affect airway
inflammation. For example, a study of Japanese
patients with COPD showed no significant changes
from baseline in sputum neutrophils or other inflam-
matory markers with salmeterol/fluticasone for
12 weeks when compared with placebo [33].
Eosinophilic airway inflammation, which is commonly
found in patients with asthma, also occurs in some
patients with COPD [34]. High blood and/or sputum eo-
sinophil counts are often associated with an increased
risk of COPD exacerbations, [35, 36] and may be a
marker of response to ICS therapy [37–39].
Clinical effects
Early randomized-controlled trials (RCTs) have demon-
strated the clinical benefits of inhaled fluticasone propi-
onate in patients with moderate-to-severe COPD [40,
41]. In these trials, fluticasone was associated with sig-
nificantly lower rates of moderate or severe exacerba-
tions compared with placebo over 6 months, [41] or
3 years [40].
Subsequent studies have shown that ICS/LABA
combination therapy is more effective than ICS
alone, particularly with regard to reducing exacerba-
tions, [5] but has no effect on long-term survival. In
the Towards a Revolution in COPD Health
(TORCH) trial, fluticasone propionate/salmeterol was
associated with a slight reduction in mortality risk
compared with placebo, but this reduction was not
statistically significant [42]. The mortality risk also
did not significantly differ between fluticasone/sal-
meterol and salmeterol alone, but was significantly
lower with the combination therapy than fluticasone
alone (p = 0.007) [42]. A subsequent analysis of data
from the TORCH study suggested that any mortality
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was more likely attributable to the salmeterol com-
ponent [43]. In the Study to Understand Mortality
and Morbidity (SUMMIT) in patients with moderate
COPD and increased cardiovascular risk, fluticasone
furoate/vilanterol had no significant effect on all-
cause mortality or cardiovascular outcomes com-
pared with placebo [44].
The beneficial effects of ICS therapy in preventing or
reducing exacerbations appear to be limited to patients
with eosinophilic inflammation. In a randomized study
of patients with COPD, a 62% mean reduction in the fre-
quency of severe exacerbations was observed when
COPD management was aimed at minimizing sputum
eosinophil levels compared with conventional guideline-
based management [45]. In a post hoc analysis of two
randomized, double blind trials, the combination of
vilanterol/fluticasone furoate was shown to reduce
COPD exacerbations by 29% in patients with eosinophil
counts of ≥2% and by 10% in patients with eosinophil
counts of <2% compared with vilanterol alone [46]. In a
post hoc analysis of the Foster 48-Week Trial to Reduce
Exacerbations in COPD (FORWARD), the beneficial ef-
fects of beclomethasone dipropionate/formoterol fumar-
ate (ICS/LABA) versus formoterol fumarate alone with
regard to reductions in exacerbations were most evident
in patients with peripheral blood eosinophilia (≥279.8
cells/μL) [39]. Similarly, a pooled analysis of two 12-
month RCTs showed that patients with >2.4% blood eo-
sinophils potentially achieve the greatest reductions in
exacerbations with ICS/LABA therapy versus LABA
alone [38]. An analysis of the Inhaled Steroids in Ob-
structive Lung Disease in Europe (ISOLDE) trial indi-
cated that a baseline blood eosinophil count ≥2% was
associated with a significantly reduced rate of FEV1 de-
cline with fluticasone propionate versus placebo (p =
0.003), while there was no difference in FEV1 decline
among those with <2% eosinophils [37].
However, when comparing the efficacy of ICS with that
of long-acting bronchodilators the results are usually fa-
vorable to the latter. LAMA alone has been shown to be
as effective as ICS/LABA therapy with regard to improve-
ments in lung function and preventing exacerbations in
patients with COPD. In the Investigating New Standards
for Prophylaxis In Reducing Exacerbations (INSPIRE)
study of patients with severe or very severe COPD and a
history of exacerbations, the annual rate of exacerbations
showed no difference between fluticasone propionate/sal-
meterol and tiotropium bromide alone, although the inci-
dence of pneumonia was significantly higher with
fluticasone propionate/salmeterol (p = 0.008) [47].
The LABA/LAMA combination indacaterol/glycopyrro-
nium was associated with significantly greater improve-
ments in lung function over 26 weeks compared withfluticasone/salmeterol (p < 0.001) in the Efficacy and safety
of once-daily indacaterol/glycopyrronium compared with
twice-daily salmeterol–fluticasone in patients with chronic
obstructive pulmonary disease (ILLUMINATE) trial, [48]
and significantly reduced the rate of moderate or severe ex-
acerbations with a lower rate of pneumonia in A 26-week
treatment randomized, double-blind, double dummy,
parallel-group study to assess the efficacy and safety of
indacaterol/glycopyrronium (LANTERN) trial [49]. In the
Effect of indacaterol/glycopyronium vs fluticasone/salme-
terol on COPD exacerbations (FLAME) trial, the annual
rate of COPD exacerbations was also found to be signifi-
cantly (11%) lower with indacaterol/glycopyrronium than
fluticasone/salmeterol over 12 months (p = 0.003) in pa-
tients with a previous history of at least one exacerbation. It
is important to indicate that patients with a history of
asthma and/or blood eosinophil counts >600 cells/μL were
excluded form FLAME [50].Adverse effects of inhaled corticosteroids
Accumulated evidence from clinical trials indicates that
ICS therapy is associated with a high risk of pneumonia,
oral candidiasis, hoarse voice, and skin bruising [2, 4, 5, 9,
10]. The risk of pneumonia is increased in older patients
(aged ≥55 years), current smokers, and patients with a his-
tory of exacerbations or pneumonia, a body mass index
<25 kg/m2, dyspnea, and/or severe airflow limitation [2, 9].
In a meta-analysis of RCTs in patients with COPD,
inhaled fluticasone or budesonide was associated with
a significant (57%) increase in the risk of pneumonia
(p < 0.0001) [51]. However, an observational cohort
study of patients with COPD found that the rates of
pneumonia and hospitalization were significantly
higher with fluticasone/salmeterol than budesonide/
formoterol (p < 0.001), which suggests there are intra-
drug class differences in the risks of pneumonia with
ICS/LABA combination therapies [52].
Long-term ICS exposure may also be associated with an
increased risk of bone fractures in patients with COPD
[53]. A meta-analysis of RCTs and observational studies
indicated a significant (27%) increase in the risk of frac-
tures with fluticasone or budesonide therapy (p = 0.04)
[53]. Osteoporosis and COPD are also strongly correlated
due to common lifestyle risk factors (eg physical inactivity,
poor diet, and smoking), COPD-associated inflammation,
and vitamin D deficiency [54].
Other adverse effects associated with the use of ICS in-
clude an increased risk of new-onset diabetes or diabetes
progression, [55] cataracts, [56] and tuberculosis [57]. In a
database cohort study of patients with respiratory disease,
ICS therapy was associated with a 34% increase both in
the risk of new-onset diabetes and in the risk of diabetes
progression [55].
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The excessive and inappropriate use of ICS in COPD
together with the increased risk of adverse effects associ-
ated with its use makes it necessary to discontinue this
treatment in patients in which the risks overweight the
possible benefits. Withdrawal of ICS has been analyzed
in several studies.
In patients with COPD, ICS withdrawal was associated
with several clinical disadvantages in early studies
(Table 1). As part of the ISOLDE trial, [40] an observa-
tional study compared patients who were receiving ICS
at study entry with those who were not on ICS [58]. In
this 8-week study, ICS withdrawal was associated with
more exacerbations, indicating that patients should be
monitored carefully following abrupt ICS discontinu-
ation [58]. In the Effect of discontinuation of inhaled
corticosteroids in patients with chronic obstructive
pulmonary disease (COPE) study, withdrawal of inhaled
fluticasone led to a higher risk of exacerbation and a sig-
nificant decline in quality of life [59]. Likewise, discon-
tinuation of fluticasone was associated with a decline in
lung function and an increase in dyspnea and mild exac-
erbations in the COPD and Seretide: a Multicenter
Intervention and Characterization (COSMIC) trial, [60]
and a worsening of symptoms and increased risk of ex-
acerbations in the Withdrawal of inhaled corticosteroids
in people with COPD in primary care (WISP) trial [61].
However, a meta-analysis of the WISP, COPE, and
COSMIC trials indicated that ICS withdrawal was not
associated with a significant increase in the risk of exac-
erbations [62]. The definition of exacerbation differed
between these early studies and the use of other medica-
tion was not reported [62]. A more recent and robust
meta-analysis concluded that ICS discontinuation did
not significantly increased the overall rate of COPD
exacerbations, although an increased risk of severe exac-
erbations was detected [63]. The increased risk of all
types of exacerbations following ICS withdrawal
observed in early studies was most likely due to a lack of
alternative COPD medications.
Evidence from more recent RCTs and real-life studies
supports the hypothesis that the ICS therapy can be
safely withdrawn in patients with stable COPD (Table 1).
In the Withdrawal of Inhaled Steroids During Optimized
Bronchodilator Management (WISDOM) trial, in which
the safety of gradual ICS withdrawal in patients previ-
ously on ICS/LABA/LAMA triple therapy was evaluated,
there was no significant difference in the risk of moder-
ate or severe COPD exacerbation over 12 months after
ICS withdrawal compared with ongoing triple therapy
[64]. Although a significantly greater decrease in FEV1
was observed at 18 weeks after ICS withdrawal (mean
difference 38 mL vs continued ICS; p < 0.001), [63] thiswas less than half of what is considered as the minimum
clinically important difference. A post hoc analysis of
WISDOM showed that patients who stopped ICS expe-
rienced a similar disease course with regard to lung
function to those who continued ICS therapy [64]. Al-
though deterioration of lung function was observed after
ICS withdrawal, these changes were small, not progres-
sive and not predictive of clinically important changes
over the duration of study follow-up [65].
By contrast, in the Indacaterol: Switching Non-exacerbating
Patients with Moderate COPD from Salmeterol/Fluticasone
to Indacaterol (INSTEAD) trial, there were no clinically
relevant reductions in lung function or differences in dyspnea
or health status over 26 weeks among patients who switched
to indacaterol compared with those who continued
fluticasone/salmeterol therapy [66]. The annual rate
of mild, moderate, or severe COPD exacerbations also
showed no significant difference between the groups.
The INSTEAD trial concluded that patients with
moderate airflow limitation and no history of exacer-
bations can be switched from fluticasone/salmeterol
to indacaterol monotherapy without loss in treatment
efficacy [66].
In the Real-life study on the appropriateness of treat-
ment in moderate COPD patients (OPTIMO), the risk
of exacerbations did not significantly increase over
6 months after ICS withdrawal compared with continued
ICS/bronchodilator therapy [67]. There was also no evi-
dence of deterioration in COPD symptoms or lung func-
tion over 6 months following ICS withdrawal [67].
Consistent with these findings, a subgroup analysis of
patients on ICS prior to study entry in the Outpatient
care with long-acting bronchodilators: COPD registry in
Germany (DACCORD) showed that ICS withdrawal was
not associated with an increase in the risk of exacerba-
tions or an increased risk of health status deterioration
compared with continued ICS therapy [68]. Indeed, in
the second year of follow-up in DACCORD, the annual
rate of exacerbations was lower among patients who
underwent ICS withdrawal than in those who continued
ICS therapy [68].
ICS withdrawal may also provide clinical benefits in pa-
tients by reducing the risk of adverse effects, particularly
pneumonia. In a population-based cohort study, ICS with-
drawal in patients with COPD was associated with a 37%
decrease in the rate of serious pneumonia over 3 years,
with a 20% risk reduction over the first month [69]. Of
note, patients who discontinued fluticasone showed
greater reductions in severe pneumonia risk than those
who discontinued budesonide [69]. These findings indi-
cate that the beneficial effects of ICS withdrawal may
occur soon after treatment discontinuation.
In a subanalysis of exacerbation rates by previous therapy
in the FLAME trial, among patients who had previously
Ta
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domized to LABA/LAMA had a significantly lower risk of
exacerbations than those who continued ICS/LABA therapy
(risk ratio 0.88; 95% confidence interval 0.80–0.97) [50].
Additionally, the effect of glyCopyrronium or indacateRol
maleate and glYcopyrronium bromide fixed-dose combin-
ation on SympToms and heALth status in patients with
moderate COPD (CRYSTAL) study of symptomatic patients
with moderate COPD previously on ICS/LABA, LABA or
LAMA therapy showed that switching to indacaterol/glyco-
pyrronium was associated with significant improvements in
trough FEV1 over 12 weeks [70].
In a subanalysis of the WISDOM study, patients with
severe or very severe COPD and a history of exacerba-
tions who had blood eosinophil counts of ≥4% (≥300
cells/μL) were at an increased risk of exacerbations fol-
lowing ICS withdrawal compared with those with lower
eosinophil counts [71]. In fact, the risk of exacerbation
after withdrawal was significantly increased in patients
who suffered 2 or more exacerbations the previous year
and had blood eosinophil counts >300 cells/μL. In
addition, these patients experienced a mean decrease of
109 mL in FEV1 compared with the mean decrease of
43 mL for the whole population [72]. This suggests that
ICS withdrawal may have deleterious effects in a sub-
population of patients with higher blood eosinophil
counts and frequent exacerbations.Proposed algorithm for ICS withdrawal in patients with
COPD
The proposal for managing ICS withdrawal in patients
with COPD takes three clinical parameters into account:
a) whether or not there is a history of previous exacerba-
tions; b) whether FEV1 is more or less than 50%; and c)
whether the patient has criteria for ACO (which in the
Spanish guidelines includes patients with COPD and
blood eosinophil counts >300 cells/μL and/or a post-
bronchodilator response of >400 mL and 15% in FEV1)
[73]. Based on these clinical parameters, patients with
COPD may be classified into three categories: (i) pa-
tients in whom the risks associated with ICS withdrawal
exceed the benefits; (ii) those in whom the benefits of
ICS withdrawal are greater than the risks; and (iii) those
in whom the risks and benefits of ICS are balanced. A
summary of this patient classification and how lung
function and exacerbation history affect the benefits and
risks of ICS withdrawal is shown in Fig. 1. Taking these
categories into consideration, the decision to withdraw
or continue ICS is based on the following:
1. In patients with COPD, FEV1 > 50% and no previous
exacerbations, the benefits of ICS withdrawal exceed
risks and ICS must be withdrawn.2. In patients with ACO and exacerbations in the
previous year, the risks associated with ICS
withdrawal exceed the benefits and ICS should not
be withdrawn.
3. Patients with FEV1 > 50% and exacerbations in the
previous year and patients with FEV1 < 50% without
exacerbations have an intermediate level of risk
associated with ICS withdrawal. The risk of
exacerbations after ICS discontinuation is low, but
dual bronchodilator therapy should be maintained to
make sure that the risk of exacerbations does not
increase.
4. Patients with FEV1 < 50% and exacerbations in the
previous year, together with patients with ACO
without exacerbations, may have an increased risk of
exacerbations after ICS withdrawal. Discontinuation
should be considered only in patients with a
significant risk of serious ICS-related adverse effects.
In these patients, ICS withdrawal may still be
possible provided that dual bronchodilator ther-
apy is maintained, but close follow-up is
essential.
An overview of the proposed algorithm is shown in Fig. 2.
Benefits of ICS withdrawal exceed risks
In patients with FEV1 > 50% and no exacerbations in the
previous year, the benefits of ICS withdrawal exceed the
risks and ICS therapy should be discontinued. Evidence
supporting ICS withdrawal in these patients is provided
by the OPTIMO, [67] INSTEAD, [66] and DACCORD
[74] studies, in which patients with mild or moderate
COPD had no changes in exacerbations, lung function,
or health status following ICS withdrawal.
Studies have also indicated that dual bronchodilator
therapy with a LABA/LAMA combination may be used
as an alternative to ICS/LABA therapy in patients with
moderate-to-severe COPD and a low risk of exacerba-
tions. In this group of patients, LABA/LAMA therapy
(indacaterol/glycopyrronium) was associated with im-
proved lung function and lower rates of exacerbation
and pneumonia compared with ICS/LABA therapy
(fluticasone/salmeterol) in the ILLUMINATE, [48]
LANTERN, [49] and CRYSTAL [70] studies. Therefore,
patients with an FEV1 > 50% and no exacerbations in the
previous year are candidates for ICS withdrawal, pro-
vided that dual bronchodilator therapy is continued [75].
Risks associated with ICS withdrawal exceed benefits
In patients with ACO and a history of exacerbations in
the previous year, the ICS withdrawal risks are greater
than the benefits and ICS should not be discontinued.
ACO is recognized as a distinct COPD phenotype, and
relevant clinical practice guidelines provide criteria to
enable clinicians to identify patients with COPD who
Fig. 1 Patient categories based on exacerbation history, airflow limitation and the risks of inhaled corticosteroid withdrawal. ACO, asthma-chronic
obstructive pulmonary disease overlap; B, benefits of ICS withdrawal; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; R, risks asso-
ciated with ICS withdrawal; dark green = ICS should be discontinued; red = ICS should not be withdrawn; pale green, pale red, or yellow = ICS
withdrawal should be carefully evaluated on a case-by-case basis, taking into account the risk of ICS-associated adverse effects
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ACO among patients with COPD is thought to be up to
20%, [20, 77–83] although prevalence is difficult to sti-
mate as there is no internationally accepted definition of
ACO [84, 85].
A simplified algorithm for the identification of ACO
was proposed following a consensus between the
Spanish COPD and asthma guidelines [73]. In this algo-
rithm, the first criterion to be met is a diagnosis of
COPD (ie aged ≥35 years, ≥10 pack-year smoker or ex-
smoker, and post-bronchodilator FEV1/FVC <0.7), after
which the diagnostic criteria for asthma are assessed. If
the diagnostic criteria for both COPD and asthma are
met, a diagnosis of ACO is confirmed; patients who do
not meet all of the asthma diagnostic criteria, but have a
bronchodilator response of ≥400 mL and 15% in FEV1
and/or eosinophilia of ≥300 cells/μL are also classified as
having ACO [73, 86]. Patients with non-completely re-
versible airflow obstruction but who smoked less thanFig. 2 Proposed algorithm for ICS withdrawal in patients with COPD. ACO,
FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid. ACO is dia
diagnosis or COPD and blood eosinophil counts >300 cells/μL and/or a po10 pack-years should be considered and treated like
asthmatics.
A post hoc analysis of the WISDOM trial identified a small
subgroup of patients with COPD with a significantly in-
creased risk of exacerbations after ICS withdrawal; these pa-
tients had a history of frequent exacerbations (≥2 per year)
and high baseline eosinophil counts (≥300 or ≥400 cells/μL;
defined as ACO according to Spanish guidelines), although a
history of frequent exacerbations alone was not predictive of
ICS responsiveness in the overall study population [72]. As
these patients represented a very small proportion of the
total patient population in the WISDOM study, this category
is expected to consist of a minority of the patients with
COPD.
Intermediate ICS withdrawal risk: benefit ratio
Patients with FEV1 > 50% and exacerbations in the previ-
ous year and patients with FEV1 < 50% without exacer-
bations have an intermediate risk associated with ICSasthma-COPD overlap; COPD, chronic obstructive pulmonary disease;
gnosed according to the Spanish consensus as COPD plus asthma
st-bronchodilator response of >400 mL and 15% in FEV1
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determine whether or not ICS therapy should be discon-
tinued, with the risk of ICS-related adverse effects being
taken into consideration. This recommendation is sup-
ported by evidence from the WISDOM [64] and FLAME
[50] studies, in which patients with moderate, severe, or
very severe COPD and a history of exacerbations showed
no increase in the annual rate of exacerbations after dis-
continuation of ICS and ongoing dual bronchodilator
therapy. In the FLAME study, the rate of pneumonia
was lower with LABA/LAMA than ICS/LABA therapy,
[50] and a post hoc analysis indicated that the lower rate
of exacerbations with LABA/LAMA was independent of
blood eosinophil levels [87]. Although the risk of exacer-
bations may be increased in patients with FEV1 < 50%
and exacerbations in the previous year, as well as pa-
tients with ACO without exacerbations, ICS withdrawal
needs to be considered in these patients, particularly
those with an increased risk of serious ICS-related ad-
verse effects. Following ICS withdrawal, these patients
should be maintained on dual bronchodilator therapy
and closely followed for exacerbations.
Method of ICS withdrawal
Based on clinical evidence, ICS therapy may be discon-
tinued abruptly, rather than with gradual dose reduction.
In the INSTEAD, [66] FLAME, [50] OPTIMO, [67]
CRYSTAL, [70] and DACCORD [74] studies, ICS ther-
apy was withdrawn abruptly with no apparent increase
in exacerbations or loss of lung function. WISDOM was
the only study in which the ICS dose was decreased in a
stepwise fashion [64]. Although ICS withdrawal was
associated with a significant decrease in FEV1 in this
study, the decline in lung function was only observed
after complete ICS discontinuation at 18 weeks and was
not progressive [64, 65]. This suggests that the effect of
ICS withdrawal on lung function (if any) only occurs
after complete discontinuation, and there is no need to
taper the dose in most patients. It should be noted that
the LABA used in this study was salmeterol, which has a
low intrinsic efficacy and a well-known tolerance in
terms of reduction of effect over time [88]. Particular
care should be exercised in high-risk patients with fre-
quent exacerbations or poor lung function receiving
high doses of ICS, and routine follow-up of patients after
ICS withdrawal is recommended.
Conclusions
Physicians should carefully evaluate patients and provide
individualized COPD treatment, especially when consider-
ing the initiation of ICS therapy or the safe discontinu-
ation of ICS in patients on long-term therapy. Given the
limited efficacy and the potentially serious adverse effects
and complications of long-term ICS therapy, the use ofICS should be limited to the minority of patients with
COPD in whom the treatment effects outweigh the risks,
and patients for whom safe ICS withdrawal can be
achieved should be identified.
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